Drugmaker

制药商

Cipla

西普拉

on Wednesday said it has launched a medication for managing obesity and type-2 diabetes mellitus.

周三表示，它已经推出了一种用于治疗肥胖症和2型糖尿病的药物。

The company has launched

公司已经推出了

Yurpeak

玉峰

(tirzepatide), a one-weekly injectable therapy for obesity and type-2 diabetes mellitus, two of the country's most pressing health challenges, the Mumbai-based drugmaker said in a regulatory filing.

孟买制药商在一份监管文件中表示，（tirzepatide）是一种每周一次的注射疗法，用于治疗肥胖症和2型糖尿病，这是该国最紧迫的两大健康挑战。

The company has the rights to distribute and promote Yurpeak -- the second brand of Lilly's tirzepatide in India, after Lilly received DCGI approval, it added.

该公司表示，在礼来获得印度药物监管总局 (DCGI) 批准后，公司拥有在印度分销和推广礼来替西帕肽的第二个品牌 Yurpeak 的权利。

Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet andexercise for the treatment of Type 2 diabetes and chronic weight management in adults.

Tirzepatide 是首个也是唯一的双重激动剂，可同时作用于葡萄糖依赖性促胰岛素多肽（GIP）和胰高血糖素样肽-1（GLP-1）受体，作为饮食和运动的辅助手段，用于治疗成人2型糖尿病和慢性体重管理。

Yurpeak will be available on prescription in the KwikPen device format in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, the company stated.

该公司表示，Yurpeak 将以六种剂量规格（2.5 毫克、5 毫克、7.5 毫克、10 毫克、12.5 毫克和 15 毫克）的 KwikPen 设备形式提供处方使用。

Live Events

现场活动

Commenting on the launch, Achin Gupta, Global Chief Operating Officer,

在发布会上，全球首席运营官阿钦·古普塔 (Achin Gupta) 表示，

Cipla

西普拉

Limited, said: 'The launch of Yurpeak marks a transformative moment in the fight against obesity and type 2 diabetes mellitus, two of India's chronic conditions with a heavy burden.'

有限，表示：“Yurpeak的推出标志着在对抗印度两大慢性疾病——肥胖症和2型糖尿病——的斗争中迎来了一个变革性的时刻，这两种疾病带来了沉重的负担。”

Cipla is entering this space with the same depth of expertise and scientific commitment that define its leadership in chronic diseases and in respiratory care, he added.

他补充说，Cipla 正在凭借其在慢性病和呼吸系统护理领域的专业深度和科学承诺进入这一领域。

'Our focus remains on accelerating access to globally benchmarked, future-ready therapies through collaborations like ours with

“我们的重点仍然是通过像我们这样的合作，加速获得全球基准的、面向未来的疗法，

Eli Lilly

礼来公司

, which bring together innovation, purpose, and scale to ensure advanced care reaches patients wherever they are,' Gupta said.

古普塔表示：“这些合作汇集了创新、目标和规模，以确保先进的医疗技术能够惠及世界各地的患者。”

Launch of Yurpeak in India will help expand access to tirzepatide so that more patients can benefit from this innovative therapy, the company said.

该公司表示，Yurpeak 在印度的上市将有助于扩大替西帕肽的使用范围，使更多患者能够从这种创新疗法中受益。

Eli Lilly will manufacture and supply Yurpeak to Cipla, and the price will be the same as Mounjaro, it added.

礼来公司将为Cipla生产并供应Yurpeak，价格将与Mounjaro相同，该公司补充道。

Add

添加

as a Reliable and Trusted News Source

作为一个可靠和值得信赖的新闻来源

Add Now!

立即添加！

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)